Brain Cancer Canada Grants Research Funds to Improve Survival Rates for Glioblastoma and Other Gliomas
May 25, 2023 11:00 ET
|
Brain Cancer Canada
TORONTO, May 25, 2023 (GLOBE NEWSWIRE) -- Brain Cancer Canada, a leading charity in the fight against brain cancer, is delighted to announce a $50,000 research grant to Dr. Amit Singnurkar at...
Brain Cancer Canada Awards CAD 50,000 Grant for Innovative Research to Improve Brain Cancer Diagnosis and Treatment
May 04, 2023 10:00 ET
|
Brain Cancer Canada
TORONTO, May 04, 2023 (GLOBE NEWSWIRE) -- Brain Cancer Canada is pleased to announce a $50,000 grant to support research on more effective diagnosis and treatment for adult brain cancer patients. ...
ITM, Helmholtz Munich and University Hospital Münster Announce Start of Phase I Clinical Trial with Radiotherapeutic ITM-31 for Glioblastoma
March 13, 2023 06:13 ET
|
ITM Isotope Technologies Munich SE
Garching/Munich, Munich and Münster, Germany, March 13, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, Helmholtz Munich and the Departments of...
The Voice Finalist Morgan Myles Joins the Glioblastoma Foundation® as a Celebrity Ambassador to Raise Awareness and Funding for Glioblastoma
February 22, 2023 09:08 ET
|
Glioblastoma Foundation
DURHAM, N.C., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Morgan Myles was a top three finalist on the latest season of NBC's The Voice, and now she is hopeful to use her voice in a different way — to share...
The Voice Finalist Morgan Myles Joins the Glioblastoma Foundation® as a Celebrity Ambassador to Raise Awareness and Funding for Glioblastoma
February 22, 2023 09:08 ET
|
Glioblastoma Foundation
DURHAM, N.C., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Morgan Myles was a top three finalist on the latest season of NBC's The Voice, and now she is hopeful to use her voice in a different way — to share...
FLAG Therapeutics Receives Rare Pediatric Disease (RPD) Designation for FLAG-003 for the Treatment of Children with Diffuse Intrinsic Pontine Glioma (DIPG)
January 31, 2023 13:00 ET
|
Flag Therapeutics, Inc.
RALEIGH, N.C., Jan. 31, 2023 (GLOBE NEWSWIRE) -- FLAG Therapeutics, Inc., announced today that FLAG-003, an investigational small molecule therapy for the treatment of Diffuse Intrinsic Pontine...
Glioblastoma Multiforme Treatment Market Is Estimated to Grow at CAGR Of 8.1%, 2022-2029 | Latest Industry Coverage by Douglas Insights
January 11, 2023 03:52 ET
|
Douglas Insights
Isle of Man, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Douglas Insights has added the Global Glioblastoma Multiforme treatment market research to its growing market reports. Douglas Insightsinsights tries...
Recent Advancements in Treatment will help Glioblastoma Treatment Drugs Market to Reach US$ 1.26 Bn at a CAGR of 5.7% Between Forecast Period of 2022-32 | Report by Future Market Insights, Inc.
November 07, 2022 10:30 ET
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, Nov. 07, 2022 (GLOBE NEWSWIRE) -- The global glioblastoma treatment drugs market is worth US$ 723.3 Mn as of now and is expected to reach US$ 1.26 Bn by the year 2032 at a CAGR of 5.7%...
Canadian Brain Cancer Patients Treated Unequally: Brain Cancer Canada
October 26, 2022 08:30 ET
|
Brain Cancer Canada
TORONTO, Oct. 26, 2022 (GLOBE NEWSWIRE) -- For Canadians diagnosed with brain cancer, where they live determines how much access they have to treatment, according to new research by the charity...
ITM Executes Option to In-license Targeted Radionuclide Therapy Candidate LuCaFab (ITM-31) for the Treatment of Malignant Brain Tumors
October 19, 2022 08:00 ET
|
ITM Isotope Technologies Munich SE
Exclusive license from Helmholtz Munich will enable ITM to access IP and know-how to develop and commercialize ITM-31 for glioblastoma patients Garching/Munich, Germany, October 19, 2022 – ITM...